## ONSET OF CARDIAC IRON LOADING IN A LARGE AND HOMOGENOUS COHORT OF THALASSEMIA MAJOR PEDIATRIC PATIENTS

Antonella Meloni<sup>1</sup>, Aldo Filosa<sup>2</sup>, Vincenzo Positano<sup>1</sup>, Daniele De Marchi<sup>1</sup>, Letizia Gulino<sup>1</sup>, Claudio Ascioti<sup>3</sup>, Massimo Midiri<sup>4</sup>, Gianluca Valeri<sup>5</sup>, Massimo Lombardi<sup>1</sup>, and Alessia Pepe<sup>1</sup>

<sup>1</sup>Cardiovascular MR Unit, Fondazione G. Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, <sup>2</sup>UOC Pediatria - DH Talassemia, AORNA. Cardarelli, Napoli, Italy, <sup>3</sup>Struttura Complessa di Cardioradiologia-UTIC, P.O. "Giovanni Paolo II", Italy, <sup>4</sup>Istituto di Radiologia, Policlinico "Paolo Giaccone", Palermo, Italy, <sup>5</sup>Dipartimento di Radiologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy

<u>Introduction.</u> Magnetic Resonance Imaging (MRI) by the T2\* technique allows highly reproducible and non invasive quantifications of myocardial iron burden and it is the gold standard for quantifying biventricular function parameters [1, 2]. It is important to determine the appropriate age to start MRI screening, because its high cost. Few data are available in the literature and they are contrasting [3]. So the aim of this study was to address this issue in our paediatric patients with thalassemia major (TM).


<u>Materials and methods.</u> We studied retrospectively 72 patients (47 males, 4.2-17.9 years old, mean age  $13.03 \pm 3.70$  years), enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network [4]. Myocardial iron overload was measured by T2\* multislice multiecho technique [5]. Biventricular function parameters were quantitatively evaluated by cine images. DE images were acquired to detect myocardial fibrosis [6]


**Results.** The global heart T2\* value was  $29.7 \pm 11.2$  ms (range 6.2 - 48.0 ms). No significant correlation was found between global heart T2\* value and age (Figure 1). The global heart T2\* value did not show significant differences according to the sex (male  $30.2 \pm 11.0$  ms versus female  $28.7 \pm 11.8$  ms, P=0.568). Sixteen patients (22%) showed an abnormal global heart T2\* value (<20 ms) and none of them was under 8 years of age.

Table 2 shows the correlation between global heart T2\* value and various hematological and CMR parameters. Global heart T2\* value was negatively correlated with mean serum ferritin levels (Figure 2). Odds Ratio for high serum ferritin levels (≥ 1500 ng/ml) was 8.4 (1.01-69.37, OR 95%CI) for abnormal global heart T2\* values (< 20 ms). The global heart T2\* value did not show a significant difference with respect to the chelation therapy (P=0.322). No significant correlations were found between the global heart T2\* values and the bi-atrial areas or the LV and RV morphological and functional parameters. Eight patients showed a left ventricular (LV) ejection fraction (EF) < 57% and none of them was under 7 years of age. Two patients showed a right ventricular (RV) EF < 52% and none of them was under 14 years of age.

Table 1.

	Correlation Coefficient (r)	P value
Hb pre-transfusion (g/dl)	-0.189	0.137
Ferritin levels (ng/l)	-0.517	< 0.0001
ALT (u/l)	-0.428	0.002
AST (u/l)	-0.403	0.001
Left Atrial Area (cm2)	0.203	0.172
Right Atrial Area (cm2)	0.077	0.607
LV EDVI (ml/m2)	0.025	0.857
LV ESVI (ml/m2)	0.044	0.750
LV SVI (ml/m2)	0.099	0.471
LV Mass index (g/m2)	0.076	0.581
LV EF (%)	0.183	0.181
RV EDVI (ml/m2)	0.013	0.924
RV ESVI (ml/m2)	0.149	0.278
RV SVI (ml/m2)	-0.120	0.383
RV EF (%)	-0.159	0.388





<u>Conclusion.</u> The MRI screening for both cardiac iron overload and function assessment can be started for TM patients at the age of 7 years. At this age not sedation is generally needed. If the availability of cardiac MRI is low, the serum ferritin levels could be used as a discriminating factor.

**References:** [1] Borgna-Pignatti C et al. Haematologica 2004;89:1187-93. [2] Cogliandro T et al. J Cardiovasc Med 2008;9(5):515–525. [3] Wood JC et al. Haematologica 2008; 93:917-920. [4] Meloni A et al. Int J Med Inform 2009;78(8):503-512. [5] Pepe A et al. JMRI 2006;23(5):662-668. [6] Pepe A et al. Heart 2009;95:1688–1693.